WO 2005/097119 PCT/US2005/011626

CLAIMS

1. A method of protecting a patient from one or more treatments that trigger apoptosis comprising administering to the patient a composition comprising a pharmaceutically acceptable amount of a PTEN inhibitor selected from the group consisting of compounds I-XIV.

- 2. The method of claims 1, wherein the treatment is a cancer treatment.
- 3. The method of claim 2 wherein the PTEN inhibitor is administered prior to, together with, or after a treatment for the cancer.
- 4. The method of claim [0006], wherein the treatment is chemotherapy or radiation therapy.
- 5. A method of treating a patient suffering from damage to normal tissue attributable to stress, comprising administering to the patient a composition comprising a pharmaceutically acceptable amount of a PTEN inhibitor selected from the group consisting of compounds I-XIV.
- 6. The method of claim [0007] wherein the PTEN inhibitor is administered prior to, together with, or after a treatment for a disease suffered by the patient.
- 7. A method of sensitizing cancer cells to an inhibitor of the PI3 kinase pathway comprising administering to a patient in need of such treatment a PTEN inhibitor selected from the group consisting of compounds I-XIV.
- 8. A method of treating apoptosis associated with a medical procedure comprising administering to a patient in need of such treatment a PTEN inhibitor PTEN inhibitor selected from the group consisting of compounds I-XIV.
- 9. A method of protecting a patient from radiation or chemical exposure comprising administering to the patient a composition comprising a pharmaceutically acceptable amount of a PTEN inhibitor selected from the group consisting of compounds I-XIV.
- 10. The method of claim 9 wherein the PTEN inhibitor is administered prior to, together with, or after the said radiation or chemical exposure.
- 11. A method of sensitizing cancer stem cells by exposing said cells to a PTEN inhibitor selected from the group consisting of compounds I-XIV.
- 12. The method of claim 9 wherein the PTEN inhibitor is administered prior to, together with, or after a treatment for a disease suffered by the patient.